CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

Is CJC-1295 No DAC FDA Approved? Regulatory Status Explained

Real Peptides Research TeamEditorial

Updated April 9, 20268 min read

47 WORDS

Short answer

Key takeaways

CJC-1295 no DAC is not FDA-approved and exists exclusively as a research chemical under federal regulatory classification—legal for laboratory use but not for human therapeutic administration.
The peptide's 'no DAC' formulation removes the Drug Affinity Complex, resulting in a 30–60 minute plasma half-life that clears the system within hours rather than days.
Research-grade peptides should demonstrate ≥98% purity verified by third-party HPLC and mass spectrometry testing, with certificates of analysis provided for every batch.
Legitimate suppliers operate under 'research use only' licensing that restricts sales to qualified institutions or documented research purposes—consumer-facing sales violate this framework.
The absence of FDA approval doesn't indicate safety or efficacy concerns but reflects the commercial and regulatory barriers to completing Phase III clinical trials for peptides without pharmaceutical industry sponsorship.

No—CJC-1295 no DAC is not FDA-approved for human clinical use. It's classified as a research peptide, meaning it's legal to manufacture, purchase, and use exclusively for laboratory research purposes under federal law. This isn't a loophole or grey area—it's the defined regulatory category the compound occupies. The FDA doesn't regulate research chemicals the same way it regulates drugs approved for prescription use, which creates a fundamentally different quality assurance and sourcing landscape. Misunderstanding this distinction leads researchers to either avoid legitimate peptides entirely or unknowingly purchase under-specified material from suppliers operating outside proper oversight.

We've worked with research institutions across the country navigating peptide sourcing decisions. The single biggest misconception we encounter is the assumption that 'not FDA-approved' means 'unregulated and unsafe.' That's not accurate—but the regulatory framework that does apply requires understanding how peptide synthesis, purity verification, and supplier compliance actually work in the research chemical space.

What is the FDA approval status of CJC-1295 no DAC?

CJC-1295 no DAC is not FDA-approved as a pharmaceutical drug. It's manufactured and distributed under research chemical regulations, which means it's subject to Good Manufacturing Practice (GMP) standards for chemical synthesis but not the clinical trial pathway required for prescription medication approval. The peptide is legal to produce and purchase when intended solely for in vitro or animal research—not for human consumption or therapeutic use.

The Regulatory Framework That Governs Research Peptides

The key misunderstanding about cjc-1295 no dac fda approved status comes from conflating two entirely separate regulatory pathways. FDA drug approval requires Phase I, II, and III clinical trials demonstrating safety and efficacy in humans—a process costing hundreds of millions of dollars and spanning years. Research chemicals like CJC-1295 no DAC bypass this pathway because they're not marketed for human therapeutic use. Instead, they fall under chemical manufacturing regulations enforced by the DEA, EPA, and state-level agencies depending on the compound's classification.

CJC-1295 no DAC is a synthetic analog of growth hormone-releasing hormone (GHRH) with the amino acid sequence modified to extend its half-life without the addition of Drug Affinity Complex (DAC). The 'no DAC' distinction matters because the original CJC-1295 formulation included a proprietary addition intended to prolong plasma stability—removing that component creates a shorter-acting variant that clears the system within hours rather than days. This variant became the research standard because it allows more controlled dosing protocols in experimental models.

Here's the honest answer: the absence of FDA approval doesn't mean CJC-1295 no DAC is inherently unsafe or ineffective—it means no pharmaceutical company has funded the clinical trial infrastructure to bring it through the approval pipeline. Many research peptides demonstrate promising mechanisms in preclinical studies but never progress to human trials due to cost, patent limitations, or market size constraints. The compound's regulatory status is a commercial and legal designation, not a scientific verdict on its biological activity.

What 'Research Use Only' Actually Means in Practice

When a peptide supplier labels CJC-1295 no DAC as 'for research use only,' that's not marketing language—it's a legal requirement. Under federal law, research chemicals can be manufactured and sold without FDA approval provided they're explicitly not intended for human consumption. This creates a regulatory gray zone where the compound is legal to possess and use in laboratory settings but illegal to market or administer as a therapeutic intervention.

The practical implication: legitimate peptide suppliers operate under business licenses that restrict sale to qualified research institutions, universities, or individuals purchasing for documented research purposes. Suppliers selling directly to consumers without verifying intended use are operating outside this framework—not because the peptide itself is illegal, but because the transaction violates the 'research use only' designation. This is why Real Peptides requires documentation of research intent and maintains chain-of-custody records for all transactions.

Purity verification becomes the critical quality control mechanism in this space. Without FDA batch-level oversight, the responsibility falls on the supplier to perform third-party testing—typically high-performance liquid chromatography (HPLC) and mass spectrometry (MS)—to confirm amino acid sequencing and quantify purity levels. Industry-standard research-grade peptides should demonstrate ≥98% purity with documented certificates of analysis (CoA) for every batch. Lower purity thresholds introduce unknown contaminants, synthesis byproducts, or incorrect sequences that compromise experimental validity.

Our experience shows that researchers underestimate the quality variance across suppliers. A peptide labeled 'CJC-1295 no DAC' from one supplier may contain 75% active compound with 25% synthesis impurities, while another supplier's batch tests at 99.2% purity. These aren't trivial differences—they fundamentally alter experimental outcomes and reproducibility.

Is CJC-1295 No DAC FDA Approved? Research vs Clinical Status

Regulatory Category	CJC-1295 No DAC Status	FDA-Approved GHRH Analog (Tesamorelin)	Key Difference	Bottom Line
FDA Drug Approval	Not approved—classified as research chemical	Approved for HIV-associated lipodystrophy (2010)	Clinical trials completed vs research-only status	CJC-1295 no DAC cannot be legally prescribed or marketed for human therapeutic use
Manufacturing Oversight	GMP compliance required for synthesis; third-party purity testing by supplier	FDA batch-level inspection and potency verification	Supplier self-regulation vs federal oversight	Quality variance exists across suppliers—CoA documentation is mandatory
Legal Purchase Status	Legal for research institutions and documented lab use	Prescription-only via licensed pharmacy	Intended use determines legality	Purchasing for personal consumption violates federal law regardless of supplier claims
Clinical Trial Evidence	Preclinical animal studies only; no Phase III human trials	Completed Phase III randomized controlled trials in humans	Experimental vs clinically validated efficacy	Mechanism understood but therapeutic outcomes in humans remain unproven
Purity Standards	≥98% recommended for research-grade material	USP-grade purity with defined impurity limits	Industry standard vs regulatory requirement	Research peptides lack mandated minimum purity—buyer verification essential
Half-Life and Dosing	30–60 minutes plasma half-life; clears within 2–4 hours	Similar GHRH mechanism but longer formulation stability	Both require reconstitution but dosing protocols differ	Shorter half-life allows flexible experimental dosing windows

What If: CJC-1295 No DAC Scenarios

What if I purchase CJC-1295 no DAC from a supplier that doesn't provide a certificate of analysis?

Don't proceed with the purchase. A certificate of analysis (CoA) is the only verifiable documentation of peptide purity, amino acid sequencing accuracy, and batch-specific quality control. Without it, you're purchasing an unknown compound with no traceability—synthesis errors, contamination, or incorrect sequences are undetectable without third-party testing. Reputable suppliers provide CoAs automatically with every order because purity verification is the baseline standard for research-grade material. If a supplier can't or won't provide this documentation, they're either cutting costs on testing or knowingly selling under-specified product.

What if I'm a researcher and want to transition CJC-1295 no DAC findings into human studies?

You'd need to initiate an Investigational New Drug (IND) application with the FDA, which requires preclinical safety data, proposed clinical trial protocols, manufacturing process documentation, and institutional review board (IRB) approval from your research institution. This pathway is designed for compounds transitioning from research chemicals to clinical trial candidates. The IND process can take 6–12 months and costs $50,000–$150,000 in regulatory and administrative expenses before any human subjects are enrolled. Most peptides never reach this stage because pharmaceutical companies won't fund trials without patent protection or clear market exclusivity.

What if a supplier claims their CJC-1295 no DAC is 'pharmaceutical grade' or 'clinical quality'?

That's marketing language, not a regulatory designation. Pharmaceutical-grade material requires FDA oversight of the manufacturing facility, batch-level inspection, and compliance with Current Good Manufacturing Practice (cGMP) standards that exceed standard GMP requirements for research chemicals. If the peptide isn't part of an FDA-approved drug or active IND application, it can't legally be classified as pharmaceutical grade. Suppliers using this language are either misrepresenting their product or conflating high purity (≥98%) with regulatory status. The correct terminology is 'research-grade' with documented purity levels.

The Blunt Truth About CJC-1295 No DAC and FDA Approval

Here's the bottom line: CJC-1295 no DAC will likely never be FDA-approved—not because it doesn't work, but because no pharmaceutical company has financial incentive to fund the $200–500 million clinical trial pathway for a peptide that can't be patented. The compound's mechanism is well-understood, its synthesis is straightforward, and generic manufacturers could replicate it immediately after approval. Without market exclusivity, there's no return on the regulatory investment. This is the reality for dozens of research peptides with promising preclinical data: they remain in the research category indefinitely because the commercial pathway to approval doesn't exist. If you're waiting for FDA approval to validate CJC-1295 no DAC's legitimacy, you're misunderstanding how drug development economics work.

CJC-1295 no DAC occupies a regulatory category that prioritizes scientific research over clinical access. The compound is legal, traceable, and manufactured under quality standards when sourced from suppliers who document purity and maintain proper licensing. What it isn't—and won't become—is a prescription medication available through traditional pharmaceutical channels. Understanding this distinction is what separates informed sourcing decisions from regulatory confusion.

If you're evaluating peptide suppliers, prioritize third-party testing documentation over marketing claims. Real Peptides maintains batch-specific certificates of analysis for every compound we produce, with HPLC and mass spectrometry verification performed by independent laboratories. Our small-batch synthesis ensures amino acid sequencing accuracy and ≥98% purity across our full peptide collection. The regulatory framework for research peptides places quality control responsibility on the supplier—choose one that treats it as a non-negotiable standard.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Yes, CJC-1295 no DAC is legal to purchase when intended exclusively for laboratory research purposes. It’s classified as a research chemical under federal law, which means it can be manufactured and sold without FDA approval provided it’s not marketed for human consumption or therapeutic use. Purchasing for personal use outside a documented research context technically violates the ‘research use only’ designation, though enforcement focuses primarily on suppliers making therapeutic claims rather than individual buyers.

CJC-1295 no DAC is a synthetic growth hormone-releasing hormone (GHRH) analog that stimulates endogenous GH production by binding to GHRH receptors in the pituitary gland, whereas FDA-approved therapies like recombinant human growth hormone (Genotropin, Norditropin) deliver exogenous GH directly. The mechanism differs fundamentally—GHRH analogs work upstream by triggering natural pulsatile GH release, while recombinant GH bypasses the body’s regulatory feedback loops entirely. Neither approach is inherently superior; they serve different experimental and clinical applications.

Research-grade CJC-1295 no DAC should demonstrate ≥98% purity as verified by high-performance liquid chromatography (HPLC) and confirmed by mass spectrometry. Anything below 95% purity introduces significant contaminants—synthesis byproducts, incorrect amino acid sequences, or residual solvents—that compromise experimental reproducibility. Legitimate suppliers provide batch-specific certificates of analysis showing exact purity percentages, retention times, and impurity profiles. If a supplier quotes ‘pharmaceutical grade’ without documentation, they’re misrepresenting standard research chemical specifications.

No—using CJC-1295 no DAC in human clinical trials requires an active Investigational New Drug (IND) application approved by the FDA. The IND process mandates preclinical safety data, proposed study protocols, institutional review board approval, and manufacturing documentation before any human subjects can be enrolled. Research peptides can transition from in vitro or animal studies to human trials only after completing this regulatory pathway, which typically takes 6–12 months and significant administrative investment.

The primary barrier is economic, not scientific. FDA drug approval costs $200–500 million and requires 7–10 years of clinical trials, but CJC-1295 no DAC can’t be patented because its structure and synthesis method are publicly documented. Without patent protection, generic manufacturers could replicate it immediately after approval, eliminating market exclusivity and return on investment. Pharmaceutical companies won’t fund trials for compounds they can’t protect commercially, which is why many promising peptides remain research chemicals indefinitely despite strong preclinical evidence.

Prioritize suppliers who provide third-party certificates of analysis (CoA) for every batch, showing HPLC-verified purity ≥98%, mass spectrometry confirmation of amino acid sequencing, and sterility testing if the peptide is lyophilized for reconstitution. Verify that the supplier operates under proper business licensing for research chemical distribution and maintains chain-of-custody documentation. Red flags include consumer-facing marketing language (‘pharmaceutical grade’ claims without documentation), refusal to provide CoAs, or prices significantly below market average (typically $40–$80 per milligram for high-purity CJC-1295 no DAC).

Once reconstituted with bacteriostatic water, CJC-1295 no DAC remains stable for 28 days when refrigerated at 2–8°C. The peptide degrades rapidly at room temperature due to its short plasma half-life (30–60 minutes), so proper cold storage is critical. Lyophilized (freeze-dried) powder can be stored at −20°C for 12–24 months without significant degradation, but once mixed with solvent, the 28-day window applies regardless of storage conditions. Stability beyond this period hasn’t been systematically tested in research-grade preparations.

No—’no DAC’ refers to the removal of Drug Affinity Complex, a proprietary addition in the original CJC-1295 formulation designed to extend plasma half-life. The ‘no DAC’ variant clears the system faster (2–4 hours vs 6–8 days), which many researchers prefer because it allows more controlled dosing protocols and reduces the risk of prolonged receptor desensitization. Both formulations bind to GHRH receptors with similar affinity; the difference is pharmacokinetic duration, not mechanism or potency. Shorter half-life doesn’t equate to lower efficacy—it changes experimental design flexibility.

Using CJC-1295 no DAC for personal therapeutic purposes violates its ‘research use only’ classification under federal law, though enforcement typically targets suppliers making clinical claims rather than individual users. The greater risk is quality control—peptides sourced outside regulated research channels often lack purity verification, proper storage conditions, or sterility testing, increasing the likelihood of contamination, incorrect dosing, or synthesis errors. Without institutional oversight and documented protocols, there’s no traceability or safety framework governing use.

Yes—tesamorelin (Egrifta) is an FDA-approved synthetic GHRH analog used to treat HIV-associated lipodystrophy. It shares the same mechanism as CJC-1295 no DAC (stimulating endogenous growth hormone release via GHRH receptor binding) but underwent Phase III clinical trials demonstrating efficacy and safety in humans, which CJC-1295 no DAC has not. Tesamorelin is available by prescription only and manufactured under full FDA oversight, whereas CJC-1295 no DAC remains in the research chemical category with supplier-level quality control.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA